APAC Much of the global pharma industry is talking about disruption, but Brendan Shaw, founder of Shawview Consulting and adjunct professor at the University of Sydney, has found a different mood in Asia Pacific: optimism. With Asia now accounting for about 43 percent of the global innovative pipeline and Western pharma…
China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Simcere Pharmaceutical expanding Greater China rights for Lynk’s JAK1 inhibitor zepuxitinib and Fresenius’ 10-year biosimilar collaboration with WuXi Biologics covering 37 candidates. Other updates feature AbbVie’s $757M migraine licensing deal with Brise, Minghui’s $440M Japan agreement with ASKA for…
China CD47 is a protein that stops immune cells called macrophages from destroying healthy cells, a signal many cancers exploit to avoid immune attack. After Gilead and Pfizer spent more than 7 billion USD on CD47 programmes that failed or were discontinued, much of the industry stepped away. Dr Tian Wenzhi, founder,…
USA A runthrough of the most impactful trends for the pharmaceutical industry in the US, part of our upcoming Healthcare & Life Sciences Review on the USA. MFN & Onshoring Deals: The Price of Avoiding 100% Tariffs US tariffs, or the threat of them, are having a huge impact on…
China Like most founders, my dream is to bring one of our own drugs to market and see patients genuinely benefit from our inventions Built on deep expertise in oligonucleotide chemistry, Leaderna Therapeutics is advancing a new generation of siRNA medicines for chronic diseases, with programmes spanning hypertension, dyslipidaemia and obesity.…
China Strong efficacy data attracts collaborators, but confidence shaken by other companies’ weaker results holds the whole field back Regend Therapeutics was founded in 2015 by Dr Ting Zhang and her husband, Professor Wei Zuo, to move stem cell research out of the lab and into patients. The company went on…
APAC The global AI-in-clinical-trials market is forecast to grow at a 22.6 percent CAGR through 2030, reaching roughly USD 6.5 billion, as sponsors push CROs to demonstrate concrete efficiency gains rather than incremental process tweaks. That growth is already visible on the ground in APAC: AI has moved well beyond the…
China China has rapidly become the world’s leading country for clinical trial volume, alongside the stratospheric growth of its local biotech industry, which now accounts for almost a third of the global drug development pipeline. The high speed and low cost of Chinese trials are unmatched globally. However, in a volatile…
China Chinese biotechs are now outpacing multinationals at getting drugs into pivotal trials — but MNCs still win the race to final approval. In this piece from the September 2026 edition of DIA Global Forum, Li Wang of Lilly’s China Drug Development & Medical Affairs Center digs into fresh 2023–2025 timeline…
China Excalipoint is betting that the next chapter of T-cell engagers will be written in solid tumours, where the modality is beginning to challenge the boundaries of cancer immunotherapy. Co-Founder, Chairman and CEO/CSO Dr Lei Fang explains how two decades of T-cell research underpin a differentiated pipeline, a China-first global development…
China CirCode Biomed is emerging at the forefront of a small but fast-evolving field seeking to turn circular RNA into a new class of medicines. From its roots in pioneering academic research, the Chinese biotech has moved circRNA into the clinic while building a diversified pipeline across ischaemic disease, in vivo…
China Chinese pharmaceutical companies are increasingly seeking drug approval in the EU, US, and Australia, beyond the NMPA. Daphne Smyth of Veristat has witnessed this shift firsthand, advising sponsors on data gaps, supplementary studies, and the regulatory quirks that stand in the way of a drug developed in China gaining marketing…
See our Cookie Privacy Policy Here